Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 07, 2011 16:48 ET | Source: Repros Therapeutics Inc.

Interim Data from Low Dose Oral Proellex(R) Study Supports Repros' Belief of a Return to Phase III in 2012

THE WOODLANDS, Texas, Sept. 7, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported results from the lowest three doses of its ongoing Phase II study of oral Proellex...
September 01, 2011 09:30 ET | Source: Repros Therapeutics Inc.

Repros to Present a Clinical Update for Its Androxal(R) and Proellex(R) Programs at the Rodman and Renshaw Annual Global Investment Conference on September 12th

THE WOODLANDS, Texas, Sept. 1, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX)today announced it will present an update on its Androxal® and Proellex® clinical programs...
August 09, 2011 09:25 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Reports Second Quarter 2011 Financial Results

THE WOODLANDS, Texas, Aug. 9, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the second quarter ended June 30, 2011. Financial Results...
August 03, 2011 20:05 ET | Source: Repros Therapeutics Inc.

Interim Analysis of Repros Therapeutics(R) Study of Androxal(R) in Men With Type 2 Diabetes Yields Statistically Significant and Clinically Relevant Reductions in HbA1c in Subset of Men Achieving Morning Testosterone > 450ng/dl

THE WOODLANDS, Texas, Aug. 3, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today provided unaudited top line results for an interim analysis it has performed on its Phase 2...
June 23, 2011 09:00 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics(R) Enrolls Fourth Cohort in Low Dose Proellex(R) Study

THE WOODLANDS, Texas, June 23, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has commenced enrolling subjects in the 9 mg cohort in the Company's low dose...
May 16, 2011 09:30 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Reports First Quarter 2011 Financial Results

THE WOODLANDS, Texas, May 16, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2011. Financial Results...
May 02, 2011 09:30 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics(R) Provides Clinical Update for Androxal(R) Study in Men With Type 2 Diabetes

THE WOODLANDS, Texas, May 2, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today provided a progress update for its Phase 2 clinical study of Androxal® in hypogonadal men...
March 28, 2011 09:30 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2010 Financial Results

THE WOODLANDS, Texas, March 28, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the year and fourth quarter ended December 31,...
March 16, 2011 09:30 ET | Source: Repros Therapeutics Inc.

Repros(R) Therapeutics Commences Dosing Third Cohort in Low Dose Proellex(R) Study

THE WOODLANDS, Texas, March 16, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX)today announced it has commenced dosing the 6 mg cohort in the Company's low dose study of...
March 15, 2011 10:05 ET | Source: Repros Therapeutics Inc.

Repros(R) Reports Results From Completed 1 mg Dose Cohort in Low Dose Proellex(R) Study

THE WOODLANDS, Texas, March 15, 2011 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) today announced it has completed its internal review of the results obtained for the 1 mg dose from...